September 10, Chongqing Yongren heart was approved by the national registration and listing. It is reported that "Yong Renxin" is China's first officially marketed implantable ventricular assist device, filling the gap in the market of ventricular assist device." The successful listing of "Yongrenxin" artificial heart is an innovative development of medical devices, promoting the progress of high-end medical devices in China. It also means that in the future, there will be more urgent need for heart transplantation of advanced heart failure patients, such as obtaining the aid of artificial heart,to the society plays a meaningful contribution.
"Yongrenxin" is a research and development product introduced from Japan by Chongqing Yongrenxin Medical Devices Company Limited, which started production in Chongqing in 2014 and launched clinical trials of "Yongrenxin" in 2018. Successful implantation of 15 cases, implantation surgery patients did not appear clinical serious complications, have been restored to health, and then approved by the state successfully listed.
It is understood that the artificial heart in the international market is priced at 800,000 to 1 million yuan, for the average patient's family, is a huge financial burden , and after the domestic production of mass production, the selling price compared to the U.S. and Japan, and other international prices, will be reduced by about 30%. Price is relatively favorable, to a large extent, can reduce the burden on the patient's economy.
It is reported that the "Yongren heart" ventricular assist device listed,expected sales next year will reach more than ten million level, and China's research and development of the third-generation artificial heart is expected to be listed two years later, and the clinical to achieve a wide range of promotion will need to go. Clinical to achieve a wide range of promotion still need to go a long way. Because the artificial heart as an artificial device implanted in the human body, there are still many more difficult problems to face.
The artificial heart is the equivalent of an implanted pump, through which blood is pumped throughout the body. It is understood that the blood flow through the artificial pump, may also form a thrombosis problem; artificial pumps need access to power drive in order to run, and the skin on the external wire wound may form an infection; advanced heart failure patients physical characteristics and conditions will be different, implantation of complications may occur, the complications may also be different. The existence of these problems can constrain the widespread use of artificial hearts.